Replies to post #928 on SurModics Inc (SRDX)

[foolishpremise]

A little silver to line the dusky earnings cloud:

1)Cancelling Cypher NXT does not mean cancelling Cypher Elite. i.e. the Cypher line may well still continue until lack of marketshare kills it some years hence. We also skip a generation (Cypher NXT) that we don't have lubricity revenue on...for one which we do (the Elite).

2)The SRDX lubricity coated Costar could potentially be sold in Europe as early as next quarter.

3)Ivation is in animal trials with both small and large (Lucentis?)molecules.

[aslan2772]

Re: Ivation Phase 2

"That SRDX will proceed to a self-funded phase-2 trial using triamcinolone suggests to me that the interest from prospective partners in using the I-vation device with their own drugs is modest. "

Dew, perhaps several parties are sincerely interested, yet Surmodics hasn't been able to secure what they consider a fair royalty rate for I-vation. Commencing a phase 2 trial with triamcinolone should increase the value of the device.

On a related note, SRDX has said they might secure a partner for funding the phase 2 with triamcinolone. This surprised me, because I worry that such a partnership could leverage SRDX into an exclusive license for the delivery platform. Perhaps giving an exclusive is simply the reality of the climate. Thoughts on this?